RecruitingNCT06405321
Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma
Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study in Guangxi, China (GUIDANCE)
Sponsor
Guangxi Medical University
Enrollment
2,000 participants
Start Date
Jan 1, 2019
Study Type
OBSERVATIONAL
Conditions
Summary
This multicenter retrospective study which included patients with hepatocellular carcinoma (HCC) who received conversion or neoadjuvant therapy to explore the best treatment options and the best benefit group.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria4
- Histologically or clinically confirmed diagnosis of HCC.
- Patients who received conversion or neoadjuvant therapy as initial treatment, including hepatic artery infusion chemotherapy (HAIC), transcatheter arterial chemoembolization (TACE), tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), or radiotherapy.
- Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0 or 1.
- With Child-Pugh 5\~7 scores.
Exclusion Criteria3
- Concurrent with other malignancies within 5 years.
- Incomplete medical data.
- Follow-up time less than 3 months.
Interventions
DRUGConversion or neoadjuvant therapy.
Patients with hepatocellular carcinoma received conversion or neoadjuvant therapy.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06405321
Related Trials
Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients
NCT056298451 location
Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid Tumors
NCT060775911 location
Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
NCT0552895214 locations
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
NCT054683592 locations
Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab
NCT0679611410 locations